2023, Number 1-3
Basic measures aimed at doctors to prevent or detect glucocorticoid-induced osteoporosis
Peralta-Pedrero ML, Cruz-Avelar A
Full text
10.35366/115243
Language: Spanish
References: 5
Page: 23-26
PDF size: 135.28 Kb.
ABSTRACT
Glucocorticoid-induced osteoporosis is a common, under-reported, and potentially serious adverse event. The general practitioner and specialists outside of rheumatology, such as family doctors, dermatologists, allergists, pulmonologists, gastroenterologists, among others, must prevent or detect this adverse event. When the patient's risk is evaluated before starting treatment with glucocorticoids, it is possible to take early actions that minimize the accelerated bone deterioration at the beginning of therapy. The FRAX tool is useful for calculating the 10-year risk of fragility fractures, but the presence of autoimmune diseases, not just rheumatoid arthritis, must be considered, as they are themselves a risk factor for osteoporosis. Bone mineral density and/or FRAX values are complementary parameters in the health professional's decision making; the dose per day, cumulative dose per year, time and route of administration, type of glucocorticoid, presence of morbidities that by themselves or due to their treatment interfere with bone health, lifestyle, constitutional characteristics of the patient, must also be evaluated personal history of fragility fractures and family history of hip fracture. Twenty-six considerations are presented to prevent or early detect osteoporosis secondary to the use of glucocorticoids.REFERENCES